Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 18, 2013

Transition Bags $7M from Lilly for Rights to Type 2 Diabetes Candidate

  • Transition Therapeutics this week said Eli Lilly and Company has exercised its option to assume all development and commercialization rights related to type 2 diabetes candidate TT-401, earning the biopharma a $7 million milestone payment from the drug giant.

    TT-401 is a dual agonist of the Glucagon-Like Peptide-1 (GLP-1) and glucagon receptors being developed to treat type 2 diabetes and accompanying obesity. Transition and Lilly entered into a licensing and collaboration agreement related to the candidate in March 2010, through which the former firm acquired the rights to a series of pre-clinical compounds from the latter, TT-401 included.

    As a result of this most recent deal, Lilly will assume all costs and perform all future development and commercialization activities for TT-401. Transition, meanwhile, will pay Lilly $14 million in three separate installments during Phase II clinical study.

    Should TT-401 be successfully commercialized, Transition will be eligible to receive approximately $240 million in additional milestone payments, it said. The firm would also be eligible to receive a double-digit royalty on sales of TT-401 products and a low, single-digit royalty on related compounds.

    "We are encouraged by the early data seen to date with TT-401, and are pleased by the efficient and thorough process by which Transition Therapeutics conducted the Phase I studies," Lilly’s David Moller, vp, endocrine and cardiovascular research and clinical investigation, said in a statement. "We look forward to continuing the development of TT-401, as it supports our strategy of offering a broad portfolio of therapies for people with diabetes."

    Transition chairman and chief executive Tony Cruz, Ph.D., added: “We are very pleased with Lilly's commitment to the development of TT-401. …Our additional financial contribution secures a greater vested interest for Transition, and we welcome the opportunity to invest in this drug candidate that has shown encouraging data in the recently announced human proof-of-concept study.”

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »